Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Lilly said the plant will strengthen its global supply chain and expand the capacity for its growing portfolio of oral ...

Trump administration pressure on Big Pharma to focus investment on the US has raised concerns in Europe, and specifically the ...

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the ...

Eli Lilly plans to build a $3 billion manufacturing facility in the Netherlands to expand its capacity to produce oral medicines. The pharmaceutical company said Monday that the new facility will be ...

Along with the company’s investment plans in Puerto Rico, Lilly also announced plans to build a $5 billon manufacturing plant ...

The Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and ...

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio ...